Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.
Tirzepatide continues to turn heads in metabolic research, and this new case report just added another piece to the puzzle. Researchers followed a 60-year-old man who dropped 60 pounds in six months using tirzepatide. Along the way, he developed right-sided brachial plexopathy—think scapular pain, tingling, and weakness. The nerve tests backed it up: clear denervation at C5-C7 roots, even though imaging showed nothing remarkable.
Pain Med Case Rep
by Wen J, Dwyer S, Kou M et al.
“Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report. Wen J(1), Dwyer S(2), Kou M(2), Alam A(3), Silva J(4), Elahi F(5). Author information: (1)California Northstate University College of Medicine, CA. (2)California Northstate University College of Medicine, Elk Grove, CA. (3)University of California, Davis, Davis, CA. (4)Sutter Roseville Medical Center, Emergency Medicine, Roseville, CA. (5)California Center Pain Medicine & Rehabilitation, Sacramento, CA. BACKGROUND: Weight reduction and metabolic changes have been associated with the development of compressive peripheral neuropathies. CASE REPORT: We present the case of a right-handed 60-year-old man who had a medical history of hypertension and hypercholesterolemia and developed neuromuscular symptoms after being treated with tirzepatide. During a 6-month course of tirzepatide use, the patient lost 60 pounds. However, the treatment was complicated by right-sided brachial plexopathy symptoms, including scapular pain, paresthesia, and progressive triceps weakness. Electromyography and nerve conduction studies confirmed denervation potentials at the right C5-C7 roots. Imaging studies were unremarkable. Symptoms persisted despite conservative interventions but improved gradually after the tirzepatide regimen was ended. At 2 months after the cessation, the patient's pain decreased from a 5/10 score to a score of one-2/10, and his strength improved. The follow-up EMG/NCV demonstrated the resolution of the denervation-caused changes. CONCLUSION: This case highlights a possible association between the rapid weight loss caused by GLP-1 RAs and the development of brachial plexopathy. In this patient's case, the latter condition improved after his medication was discontinued. Copyright: 2026, American Society of Interventional Pain Physicians. Conflict of interest statement: Each author certifies that he or she, or a member of his or her immediate family, has no commercial association (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted manuscript.”
Here’s the interesting part. The symptoms stuck around during the rapid weight loss, but after stopping tirzepatide, things improved. Two months later, pain scores dropped and muscle strength came back. Follow-up nerve tests showed the changes had resolved.
Key takeaways for anyone researching tirzepatide or similar GLP-1 receptor agonists:
Rapid weight loss can shift anatomy and nerve relationships, especially in older adults or those with preexisting health issues
Peripheral neuropathies, while rare, are known to pop up with fast weight reduction
In this case, stopping the peptide led to recovery—another data point for the reversibility of these effects
None of this is a knock against tirzepatide itself. The compound did its job: major weight loss, solid metabolic shifts. But it’s a reminder that researchers should track not just metabolic markers, but also musculoskeletal and neurological changes in their studies.
Curious about tirzepatide’s research profile or sourcing? Check the full rundown at tirzepatide or browse the vendor directory to see who’s supplying it for research.
Every new case adds nuance to the field—and that’s exactly how progress happens.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.